Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170837 | 0.88 | POLB (0.41) | HPGDPOLBALDH1A1CNR2CNR1 | |
| SCHEMBL10579002 | 0.87 | LIPA (0.37) | HPGDALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL17445694 | 0.83 | HPGD (0.42) | HPGDALDH1A1MEN1HTTKMT2A | |
| SCHEMBL13543224 | 0.83 | HPGD (0.47) | HPGDALDH1A1MEN1HTTKMT2A | |
| SCHEMBL13727465 | 0.81 | LIPA (0.42) | HPGDPOLBCNR2CNR1RIPK1 | |
| SCHEMBL4178019 | 0.81 | HPGD (0.50) | HPGDALDH1A1PKMMEN1HTT | |
| SCHEMBL4171831 | 0.78 | GLA (0.41) | HPGDPOLBALDH1A1DAONAAA | |
| SCHEMBL2657376 | 0.77 | KDM4E (0.38) | HPGDPOLBALDH1A1CNR2CNR1 | |
| SCHEMBL1067772 | 0.76 | GLA (0.45) | HPGDALDH1A1MEN1KMT2ANAAA | |
| SCHEMBL26723251 | 0.76 | GNAI3 (0.46) | ALDH1A1RIPK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236841-B2 | Fused heterocycle derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20090239853-A1 | Fused heterocycle derivative | KYOWA KIRIN CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2070927-A1 | FUSED HETEROCYCLIC DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239853-A1 | Fused heterocycle derivative | NR5A2, CBR3, NR3C2 | HPGD 1505/4885POLB 3438/4885ALDH1A1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.